Obesity drugs gain weight in labs: Several clinical trials by big and small pharma cos underway

Driven by the success of Wegovy and Mounjaro, numerous pharma companies are developing anti-obesity drugs, with over 170 in various stages. While giants like Novartis and GSK are cautious, Eli Lilly and Novo Nordisk lead the race. Research expands beyond GLP-1 targets, exploring oral options and addressing conditions like MASH and CVD.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/j0HGQFk
via IFTTT